A recent trial published in the Journal of American Medical Association found that subthalamic deep brain stimulation (DBS) is an effective therapy for people living with moderate to advanced Parkinson’s disease (PD)

The Implantable Neurostimulator for the Treatment of Parkinson’s Disease (INTREPID) trial tracked outcomes in 313 patients implanted with Boston Scientific’s Vercise DBS system between 2013 and 2022. This study followed participants for 5 years, making it one of the most comprehensive long-term DBS trials to date.

Of the 191 patients who received DBS, 137 completed the 5-year follow-up. At baseline, the participants had significant motor impairment, with average Unified Parkinson’s Disease Rating Scale (UPDRS-III) scores of 42.8 in the “off medication” state. By year one

See Full Page